CFTN Interview | Sanofi-Blueprint Merger
[CTFN Interview on Sanofi’s proposed acquisition of Blueprint Medicines]
Ryan Lynch recently interviewed me for his piece on the Federal Trade Commission’s review of Sanofi’s proposed acquisition of Blueprint Medicines. The focus is whether Sanofi’s control over both Dupixent and Blueprint’s BLU-808 could raise competitive concerns, even if the drugs are not direct substitutes.
As I noted, “Even if they’re not direct substitutes, the ability to control how each is developed, positioned, and marketed could raise flags, especially if one could be used to block uptake of the other preemptively.”
Honored to be featured alongside Professor Michael Carrier of Rutgers Law School.
https://lnkd.in/ggK6mgRy Penn State Dickinson Law
hashtagAntitrust hashtagInnovationPolicy hashtagPharmaLaw hashtagMergersAndAcquisitions hashtagCTFN hashtagFederalTradeCommission hashtagCompetitionLaw hashtagIPandInnovation
